Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration.

Patel MM, Nielsen DA, Kosten TR, De La Garza R 2nd, Newton TF, Verrico CD.

Am J Addict. 2018 Oct;27(7):567-573. doi: 10.1111/ajad.12788. Epub 2018 Aug 20.

PMID:
30126012
2.

Psychosis and synthetic cannabinoids.

Deng H, Verrico CD, Kosten TR, Nielsen DA.

Psychiatry Res. 2018 Oct;268:400-412. doi: 10.1016/j.psychres.2018.08.012. Epub 2018 Aug 10. Review.

PMID:
30125871
3.

Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study.

Mathai DS, Holst M, Rodgman C, Haile CN, Keller J, Hussain MZ, Kosten TR, Newton TF, Verrico CD.

J Neuropsychiatry Clin Neurosci. 2018 Winter;30(1):66-76. doi: 10.1176/appi.neuropsych.16120328. Epub 2017 Jun 23.

PMID:
28641496
4.

"Just one bad high:" considering synthetic cannabinoid outcome expectancies in adolescents.

Mathai DS, Verrico CD, Shorter D, Coverdale JH, Kosten TR.

Am J Addict. 2016 Oct 17. doi: 10.1111/ajad.12457. [Epub ahead of print]

PMID:
27749024
5.

Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial.

Rodgman C, Verrico CD, Holst M, Thompson-Lake D, Haile CN, De La Garza R 2nd, Raskind MA, Newton TF.

J Clin Psychiatry. 2016 May;77(5):e561-5. doi: 10.4088/JCP.14m09681.

PMID:
27249080
6.

Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.

Verrico CD, Haile CN, De La Garza R 2nd, Grasing K, Kosten TR, Newton TF.

Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw029. doi: 10.1093/ijnp/pyw029. Print 2016 Jul.

7.

Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder.

De La Garza R 2nd, Verrico CD, Newton TF, Mahoney JJ 3rd, Thompson-Lake DG.

Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv098. doi: 10.1093/ijnp/pyv098.

8.

Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans.

Newton TF, Haile CN, Mahoney JJ 3rd, Shah R, Verrico CD, De La Garza R 2nd, Kosten TR.

Psychiatry Res. 2015 Nov 30;230(1):44-9. doi: 10.1016/j.psychres.2015.07.073. Epub 2015 Jul 29.

9.

Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone.

Rodgman CJ, Verrico CD, Worthy RB, Lewis EE.

Prim Care Companion CNS Disord. 2014 Aug 14;16(4). doi: 10.4088/PCC.13l01594. eCollection 2014. No abstract available.

10.

A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disorders.

Mahoney JJ 3rd, Thompson-Lake DG, Cooper K, Verrico CD, Newton TF, De La Garza R 2nd.

J Psychopharmacol. 2015 Jan;29(1):50-6. doi: 10.1177/0269881114560182. Epub 2014 Nov 25.

PMID:
25424624
11.

The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders.

Mahoney JJ 3rd, De La Garza R 2nd, Jackson BJ, Verrico CD, Ho A, Iqbal T, Newton TF.

Psychiatry Res. 2014 Oct 30;219(2):367-71. doi: 10.1016/j.psychres.2014.05.026. Epub 2014 May 27.

12.

Short-term, low-dose varenicline administration enhances information processing speed in methamphetamine-dependent users.

Kalechstein AD, Mahoney JJ 3rd, Verrico CD, De La Garza R 2nd.

Neuropharmacology. 2014 Oct;85:493-8. doi: 10.1016/j.neuropharm.2014.05.045. Epub 2014 Jun 12.

PMID:
24930359
13.

Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study.

Verrico CD, Haile CN, Mahoney JJ 3rd, Thompson-Lake DG, Newton TF, De La Garza R 2nd.

Drug Alcohol Depend. 2014 Aug 1;141:72-8. doi: 10.1016/j.drugalcdep.2014.05.008. Epub 2014 May 28.

14.

Repeated Δ9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory.

Verrico CD, Gu H, Peterson ML, Sampson AR, Lewis DA.

Am J Psychiatry. 2014 Apr;171(4):416-25. doi: 10.1176/appi.ajp.2013.13030335.

15.

Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers.

Verrico CD, Mahoney JJ 3rd, Thompson-Lake DG, Bennett RS, Newton TF, De La Garza R 2nd.

Int J Neuropsychopharmacol. 2014 Feb;17(2):223-33. doi: 10.1017/S146114571300134X.

16.

Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers.

Mahoney JJ 3rd, Kalechstein AD, Verrico CD, Arnoudse NM, Shapiro BA, De La Garza R 2nd.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:137-42. doi: 10.1016/j.pnpbp.2013.11.001. Epub 2013 Nov 12.

17.

Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.

Verrico CD, Haile CN, Newton TF, Kosten TR, De La Garza R 2nd.

Expert Opin Investig Drugs. 2013 Dec;22(12):1549-68. doi: 10.1517/13543784.2013.836488. Epub 2013 Sep 14. Review. Erratum in: Expert Opin Investig Drugs. 2014 Jun;23(6):885. De La Garza, Richard [corrected to De La Garza, Richard 2nd].

18.

Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.

Volk DW, Siegel BI, Verrico CD, Lewis DA.

Schizophr Res. 2013 Jun;147(1):53-57. doi: 10.1016/j.schres.2013.02.038. Epub 2013 Apr 2.

19.

Delay- and dose-dependent effects of Δ⁹-tetrahydrocannabinol administration on spatial and object working memory tasks in adolescent rhesus monkeys.

Verrico CD, Liu S, Bitler EJ, Gu H, Sampson AR, Bradberry CW, Lewis DA.

Neuropsychopharmacology. 2012 May;37(6):1357-66. doi: 10.1038/npp.2011.321. Epub 2012 Jan 4.

20.

Acquisition and baseline performance of working memory tasks by adolescent rhesus monkeys.

Verrico CD, Liu S, Asafu-Adjei JK, Sampson AR, Bradberry CW, Lewis DA.

Brain Res. 2011 Mar 10;1378:91-104. doi: 10.1016/j.brainres.2010.12.081. Epub 2011 Jan 6.

21.

Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.

Eggan SM, Stoyak SR, Verrico CD, Lewis DA.

Neuropsychopharmacology. 2010 Sep;35(10):2060-71. doi: 10.1038/npp.2010.75. Epub 2010 Jun 16.

22.

MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor.

Verrico CD, Lynch L, Fahey MA, Fryer AK, Miller GM, Madras BK.

J Psychopharmacol. 2008 Mar;22(2):187-202. doi: 10.1177/0269881107083639. Epub 2008 Feb 28.

PMID:
18308800
23.

MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.

Verrico CD, Miller GM, Madras BK.

Psychopharmacology (Berl). 2007 Jan;189(4):489-503. Epub 2005 Oct 12.

PMID:
16220332
24.

Primate trace amine receptor 1 modulation by the dopamine transporter.

Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK.

J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11.

25.
27.
28.
29.
30.

Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization.

George TP, Verrico CD, Picciotto MR, Roth RH.

J Pharmacol Exp Ther. 2000 Oct;295(1):58-66.

31.
32.

Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats.

Jentsch JD, Dazzi L, Chhatwal JP, Verrico CD, Roth RH.

Neurosci Lett. 1998 Dec 24;258(3):175-8.

PMID:
9885959
33.

Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat.

Jentsch JD, Verrico CD, Le D, Roth RH.

Neurosci Lett. 1998 May 1;246(3):169-72.

PMID:
9792619
34.
35.

Supplemental Content

Loading ...
Support Center